This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Avastin
  • /
  • A Study of Atezolizumab in Combination With Bevaci...
Clinical trial

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma [IMmotion151]

Read time: 2 mins
Last updated:31st May 2015
Identifier: NCT02420821

This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab (MPDL3280A) plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.


Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
Enrollment: 915
Actual Study Start Date: May 31, 2015
Estimated Study Completion Date: July 31, 2020
Estimated Primary Completion Date: July 31, 2020 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
Atezolizumab + Bevacizumab
- Active Comparator: Sunitinib

Category Value
Date last updated at source 2017-08-02
Study type(s) Interventional
Expected enrolment 915
Study start date 2015-05-31
Estimated primary completion date 2020-07-31

View full details